A DIFFERENTIATED APPROACH TO PRESCRIBING DIPEPTIDYL PEPTIDASE-4 INHIBITORS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Diabetes mellitus is one of the most common diseases. Medications from different groups are used to treat this disease. Dipeptidyl peptdase-4 inhibitors are relatively novel representatives of sugar-lowering drugs. The efficacy and safety of the drugs in patients with hepatic and renal dysfunction and their effect on cardiovascular risk are analyzed.

Full Text

Restricted Access

About the authors

A. Verbovoy

Samara State Medical University

Professor, MD

Yu. Dolgikh

Samara State Medical University

Email: yulyadoll@mail.ru
Candidate of Medical Sciences

A. Pashentseva

Samara State Medical University

Candidate of Medical Sciences

References

  1. International Diabetes Federation. The Diabetes Atlas, fourth edition (2011). http://www.idf.org/diabetesatlas.
  2. Stratton I., Adler A., Neil H. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 dia-betes (UKPDS 35): prospective observational study // BMJ. - 2000; 321: 405-12.
  3. Вербовой А.Ф., Барабанова Н.А. Фармакоэпидемиологический анализ терапии сахарного диабета 2-го типа в амбулаторной практике // Пробл. эндокринол. - 2009; 55 (4): 3-6.
  4. Holst J. The physiology and pharmacology of incretins in type 2 diabetes // Diabet. Obes. Metab. - 2008; 10 (Suppl. 3): 14-21.
  5. Романов Г.Н. Ингибиторы дипептидилпептидазы-4: новые возможности эффективной и безопасной оптимизации углеводного обмена у пациентов с сахарным диабетом 2-го типа // Мед. новости. - 2013; 3: 15-9.
  6. Wei Y., Mojsov S. Tissue-specifi c expression of the human receptor for glucagon-like peptide 1: brain, heart and pancreatic forms have the same deduced amino acid sequences // FEBS Lett. - 1995; 358: 219-24.
  7. Ahren B. GLP-1 and extra-islet effects // Horm. Metab. Res. - 2004; 36: 842-5.
  8. Nikolaidis L., Mankad S., Sokos G. et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion // Circulation. - 2004; 109: 962-5.
  9. Read P., Khan F., Dutka D. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease // Heart. - 2012; 98 (5): 408-13.
  10. Thrainsdottir I., Malmberg K., Olsson A. et al. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure // Diabet. Vasc. Dis. Res. - 2004; 1: 40-3.
  11. Nikolaidis L., Elahi D., Hentosz T. et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy // Circulation. - 2004; 110: 955-61.
  12. Bhashyam S., Fields A., Patterson B. et al. Glucagon like peptide-1 increases myocardial glucose uptake via p38alphaMAP kinase-mediated, nitric oxidedependent mechanisms in conscious dogs with dilated cardiomyopathy // Circulat. Heart Fail. - 2010; 3: 512-21.
  13. Joseand T., Inzucchi S. Cardiovascular effects of the DPP-4 inhibitors // Diabet. Vasc. Dis. Res. - 2012; 9 (2): 109-16.
  14. Инструкция по медицинскому применению препарата Галвус (вилдаглиптин). Регистрационный номер: ЛРС-008119/08.
  15. Ligueros-Saylan M., Foley J., Schweizer A. et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials // Diabet. Obes. Metab. - 2010; 12 (6): 495-509.
  16. Macauley M., Hollingsworth K., Smith F. et al. Effect of vildagliptin on hepatic steatosis // Clin. Endocrinol. Metab. - 2015; 100 (4): 1578-85.
  17. Arase Y., Suzuki F., Kobayashi M. et al. Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus // Hepatol. Res. - 2011; 41 (6): 524.
  18. Schweizer A., Dejager S., Foley J. et al. Assessing the cardio-cerebrovascular safety of vildagliptin: metaanalysis of adjudicated events from a large Phase III type diabetes population // Diabet. Obes Metab. - 2010; 12 (6): 485-94.
  19. Инструкция по применению лекарственного препарата для медицинского применения Онглиза® (саксаглиптин) Регистрационный номер: ЛРС-008697/10.
  20. Инструкция по медицинскому применению лекарственного препарата Тражента (линаглиптин). Регистрационное удостоверение: ЛП-001430 от 12.01.2012.
  21. Graefe-Mody U., Rose P., Retlich S. et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment // Br. J. Clin. Pharmacol. - 2012; 74 (1): 75-85.
  22. He Y., Kulmatycki K., Zhang Y. et al. Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment // Int. J. Clin. Pharmacol. Ther. - 2013; 51 (9): 693-703.
  23. Lukashevich V., Schweizer A., Shao Q. et al. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial // Diabet. Obes. Metab. - 2011; 13 (10): 947-54.
  24. Schweizer A., Dejager S. Experience with vildagliptin in patients >75 years with type 2 diabetes and moderate or severe renal impairment // Diabet. Ther. -2013; 4 (2): 257-67.
  25. Ito H., Mifune M., Matsuyama E. et al. Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis // Diabet. Ther. - 2013; 4 (2): 321-9.
  26. Tani S., Nagao K., Hirayama A. Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: a pilot study // Am. J. Cardiovasc. Drugs. - 2013; 13 (6): 443-50.
  27. Mori H., Okada Y., Arao T. et al. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus // J. Diab. Invest. - 2014; 5 (3): 313-9.
  28. Инструкция по медицинскому применению препарата Янувия (ситаглиптин). Регистрационный номер: ЛРС-003200/07.
  29. Kothny W., Lukashevich V., Foley J. et al. Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial // Diabetologia. - 2015; [Epub. ahead of print].
  30. Frederich R., McNeill R., Berglind N. et al. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial // Diabetol. Metab. Syndr. - 2012; 4 (1): 36.
  31. Udell J., Bhatt D., Braunwald E. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial // Diabet. Care. - 2015; 38 (4): 696-705.
  32. Экспертный совет по применению нового ингибитора ДПП-4 ТРАЖЕНТА (линаглиптин) в лечении сахарного диабета 2 типа // Сахарный диабет. - 2012; 2: 103-4.
  33. Ito H., Abe M., Antoku S. et al. Comparison of the antidiabetic effects of linagliptin among groups with a normal renal function and a mild or severe renal impairment - retrospective observation study of Japanese patients with type 2 diabetes mellitus // Expert Opin. Pharmacother. - 2015; 16 (3): 289-96.
  34. McGill J., Sloan L., Newman J. et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study // Diabet. Care. - 2013; 36 (2): 237-44.
  35. Groop P., Cooper M., Perkovic V. et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction // Diabet. Care. - 2013; 36 (11): 3460-8.
  36. Cooper M., Perkovic V., McGill J. et al. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes // Am. J. Kidney Dis. - 2015; [Epub. ahead of print].
  37. Monami M., Dicembrini I., Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials // Nutr. Metab. Cardiovasc. Dis. - 2014; 24 (7): 689-97.
  38. Wu S., Hopper I., Skiba M. et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants // Cardiovasc. Ther. - 2014; 32 (4): 147-58.
  39. Fadini G., Avogaro A., Degli Esposti L. et al. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database // Eur. Heart J. - 2015; [Epub. ahead of print].
  40. Kim J., Samson S. Cardiovascular effects of incretin therapy in diabetes care // Metab. Syndr. Relat. Disord. - 2014; 12 (6): 303-10.
  41. Аметов А.С., Кулиджанян Н.К. «Инкретины» в терапии больных сахарным диабетом 2 типа: фокус на сердечнососудистую недостаточность // Эффективная фармакотерапия. - 2013; Спецвып. № 1: 26-31.
  42. Sicras-Mainar A., Navarro-Artieda R. Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly // Drug Des. Devel. Ther. - 2014; 8: 811-8.
  43. Shimodaira M., Niwa T., Nakajima K. et al. Beneficial effects of vildagliptin on metabolic parameters in patients with type 2 diabetes // Endocr. Metab. Immune Disord. Drug Targets. - 2015 [Epub. ahead of print].
  44. Аметов А.С., Карпова Е.В. Эффективное и безопасное управление сахарным диабетом 2 типа при помощи ингибиторов ДПП-4 // Сахарный диабет. - 2010; 2: 69-75.
  45. Belice T., Yuce S., Kizilkaya B. et al. Noncardiac Pulmonary Edema induced by Sitagliptin Treatment // J. Family Med. Prim. Care. - 2014; 3 (4): 456-7.
  46. Chen D., Wang S., Mao C. et al. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study // Int. J. Cardiol. - 2015; 181: 200-6.
  47. Merck. Merck announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) met primary endpoint. www.mercknewsroom.com/news-release/prescription-medicine-news/merck-announces-trial-evaluating-cardiovascular-outcomes-sit.
  48. Green J., Bethel M., Armstrong P. et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes // N. Engl. J. Med. - 2015; [Epub. ahead of print].
  49. Singh T., Vangaveti V., Malabu U. et al. Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosis-A review // Diabetes Metab. Syndr. - 2015 [Epub. ahead of print].
  50. Koren S., Shemesh-Bar L., Tirosh A. et al. The Effect of Sitagliptin Versus Glibenclamide on Ar-terial Stiffness, Blood Pressure, Lipids, and Inflammation in Type 2 Diabetes Mellitus Patients // Diabetes Technol. Ther. - 2012; [Epub. ahead of print].
  51. Scirica B., Bhatt D., Braunwald E. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus // N. Engl. J. Med. - 2013; 369 (14): 1317-26.
  52. Johansen O., Neubacher D., von Eynatten M. et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme // Cardiovasc. Diabetol. - 2012; 11 (3).
  53. Rosenstock J., Marx N., Neubacher D. et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events // Cardiovasc. Diabetol. - 2015; 14 (1): 57.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies